GLIA Diagnostics
GLIA Diagnostics is dedicated to advancing the diagnosis and understanding of traumatic brain injury (TBI), with a focus on mild TBI and concussion. They collaborate globally with medical and scientific experts, utilizing clinical trials to validate biomarkers and explore diagnostic modalities. Their mission is to develop a definitive diagnostic and prognostic tool for brain injuries, improving outcomes through research, education, and innovative technology.
Industries
Nr. of Employees
small (1-50)
GLIA Diagnostics
Neutral Bay, New South Wales, Australia, Oceania
Products
Blood-based microRNA panel for TBI diagnosis and prognosis
A plasma-based panel of microRNAs measured quantitatively to indicate presence and severity of traumatic brain injury and to provide prognostic information for return-to-activity decision-making.
Point-of-care triage test concept for frontline use
Conceptual point-of-care diagnostic intended for rapid triage in emergency or battlefield settings to support objective decision-making at the front line.
Blood-based microRNA panel for TBI diagnosis and prognosis
A plasma-based panel of microRNAs measured quantitatively to indicate presence and severity of traumatic brain injury and to provide prognostic information for return-to-activity decision-making.
Point-of-care triage test concept for frontline use
Conceptual point-of-care diagnostic intended for rapid triage in emergency or battlefield settings to support objective decision-making at the front line.
Services
Clinical trial design and biomarker validation studies
Protocol development and coordination of human studies to validate diagnostic and prognostic biomarkers for TBI, including ethics and outcome measure planning.
miRNA assay development and analytical validation
Development and optimisation of molecular assays for detection of circulating microRNAs and analytical workflows for quantitative measurement.
Integrated diagnostic strategy consulting (biomarkers, imaging, cognition)
Advisory services to combine molecular biomarkers with imaging and neurocognitive assessments for improved diagnostic and prognostic workflows.
Proteomics-based marker discovery
Proteomics approaches, including mass spectrometry, for identification of candidate protein biomarkers complementary to nucleic acid markers.
Clinical trial design and biomarker validation studies
Protocol development and coordination of human studies to validate diagnostic and prognostic biomarkers for TBI, including ethics and outcome measure planning.
miRNA assay development and analytical validation
Development and optimisation of molecular assays for detection of circulating microRNAs and analytical workflows for quantitative measurement.
Integrated diagnostic strategy consulting (biomarkers, imaging, cognition)
Advisory services to combine molecular biomarkers with imaging and neurocognitive assessments for improved diagnostic and prognostic workflows.
Proteomics-based marker discovery
Proteomics approaches, including mass spectrometry, for identification of candidate protein biomarkers complementary to nucleic acid markers.
Expertise Areas
- miRNA-based biomarker discovery
- Biomarker validation and assay optimisation
- Clinical trial design and execution for diagnostics
- Neurocognitive assessment for TBI
Key Technologies
- microRNA analysis
- RT-qPCR for small RNA quantification
- Mass spectrometry proteomics
- Blood/plasma and saliva biomarker sampling